Piper Sandler Reaffirms “Overweight” Rating for Sight Sciences (NASDAQ:SGHT)

Sight Sciences (NASDAQ:SGHT)‘s stock had its “overweight” rating reiterated by stock analysts at Piper Sandler in a report released on Thursday, Benzinga reports. They currently have a $12.00 price target on the stock, up from their previous price target of $9.00. Piper Sandler‘s price objective suggests a potential upside of 22.62% from the company’s current price.

A number of other research analysts also recently issued reports on SGHT. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. HC Wainwright started coverage on Sight Sciences in a research report on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective for the company. Citigroup increased their price objective on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, October 5th. Wall Street Zen raised shares of Sight Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, UBS Group boosted their price target on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sight Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $9.62.

Sight Sciences Stock Performance

Shares of SGHT stock traded up $0.11 during mid-day trading on Thursday, reaching $9.79. The stock had a trading volume of 315,780 shares, compared to its average volume of 274,853. The business’s fifty day moving average is $8.66 and its 200-day moving average is $6.05. The firm has a market cap of $539.11 million, a price-to-earnings ratio of -17.55 and a beta of 2.44. Sight Sciences has a 1-year low of $3.38 and a 1-year high of $10.14. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. The company had revenue of $24.92 million during the quarter, compared to analyst estimates of $23.55 million. On average, research analysts forecast that Sight Sciences will post -0.48 earnings per share for the current year.

Insider Activity

In other news, CTO David Badawi sold 7,797 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the transaction, the chief technology officer directly owned 1,975,075 shares in the company, valued at $17,874,428.75. This trade represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Paul Badawi sold 29,653 shares of Sight Sciences stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $268,359.65. Following the completion of the transaction, the chief executive officer directly owned 6,092,819 shares of the company’s stock, valued at approximately $55,140,011.95. This represents a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 47,646 shares of company stock worth $429,157 over the last quarter. 30.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Sight Sciences

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Sight Sciences in the second quarter worth approximately $16,710,000. Dimensional Fund Advisors LP raised its position in shares of Sight Sciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after acquiring an additional 40,346 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Sight Sciences by 6.3% in the first quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock valued at $1,106,000 after purchasing an additional 17,458 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Sight Sciences in the second quarter valued at approximately $908,000. Finally, Bank of America Corp DE acquired a new stake in Sight Sciences during the second quarter worth approximately $520,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher revenue outlook: Sight Sciences raised its 2026 revenue guidance to $92–$93 million and indicated a higher target of about $12 million for IDE. The updated outlook signals confidence in growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: Q3 revenue topped estimates: Revenue was $24.92 million, above analysts’ $23.55 million estimate. The quarterly loss of $0.12 per share matched expectations and narrowed from $0.16 a year earlier. Article: Sight Sciences Q3 2026 financial results
• Positive Sentiment: CMS code for TearCare: CMS established a direct practice expense supply code for TearCare’s single-use SmartLids component. This may improve payment recognition and help support use of the product, though the announcement does not specify a payment rate. Article: CMS establishes a TearCare SmartLids supply code
• Negative Sentiment: Profitability remains a concern: SGHT still reported a quarterly loss, so investors will look for revenue growth to translate into improved margins and a path toward profitability.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.